首页 > 主讲嘉宾 > 详情
王璘(武田亚洲开发中心负责人)
个人简介

王璘博士于2017年加入武田亚洲开发中心并担任负责人,致力于带领团队推动创新药物的加速开发,以服务于中国和亚洲其他国家患者的需求。王璘博士成功带领武田亚洲开发中心实现转型,并将中国提升为武田全球四大药物开发地区,力争实现在中国同步递交新药上市申请。她还积极促进将武田在亚洲的本土经验与全球药物开发战略相结合。

王璘博士拥有20多年药物开发经验,是资深医学科学研究者和制药行业的领军人物。在加入武田之前,她在赛诺菲工作了18年,其中包括在赛诺菲美国的11年就职经历。在美国期间,王璘博士是赛诺菲全球临床开发管理团队的核心成员,管理所有治疗领域以及各期临床研究的战略制定和执行。2009年,王璘博士回到上海并领导建立了赛诺菲的亚太临床开发团队,负责日本、中国、韩国以及中国台湾地区的药物开发和注册。在此期间,王璘博士带领团队在5年内完成了亚洲20 余个新药申请和补充新药申请的提交和审批。2015年至2017年间,王璘博士带领团队建立了赛诺菲亚洲生物开发部门。

王璘博士毕业于北京大学医科学院。


Lin Wang joined Takeda in 2017 as Head of Takeda Development Center Asia, responsible for leading the organization to accelerate innovative medicine development for patients in China and other countries in Asia. Dr. Wang has led the transformation of Takeda Development Center Asia and elevated China as one of Takeda’s four key regions for new pipeline development, aiming for simultaneous filing. Dr. Wang’s is also leading the efforts to incorporate Asian insights into Takeda’s global drug development strategy.

With over 20 years of experience in drug development, Dr. Wang is a physician scientist and an established leader and in the pharmaceutical industry. Prior to joining Takeda, Dr. Wang spent 18 years with Sanofi, including 11 years with Sanofi in the United States, where she was a key member of global clinical development management team overseeing clinical strategy and clinical study designs across all phases and all treatment areas. In 2009, she relocated to Shanghai and led the establishment of Sanofi Asia Pacific Development Organization, responsible for drug development and registration in Japan, China, Korea, and China Taiwan. In the position, she led the filing and approvals of over 20 New Drug Application and Supplemental New Drug Application in Asia. From 2015 to 2017, she led the efforts in building Sanofi’s Asia Biologics Development Unit.

Dr. Wang received her M.D. from Peking University Medical School.

发表论文